Bengaluru: Onco Therapies Ltd, a wholly owned subsidiary of Strides Arcolab Ltd (Strides), has received Abbreviated New Drug Application (ANDA) approval for Ifosfamide injection 50 mg/ml packaged in one gram/20 ml and three grams/60 ml single-dose vials.
Ifosfamide is a part of the onncology portfolio licensed to Pfizer for the US market and the product is available for immediate launch.
As per IMS data, the US market for generic Ifosfamide is about $15 million.
Ifosfamide is a chemotherapy drug that is usually used to treat sarcoma, testicular cancer and some types of lymphomas.
No comments:
Post a Comment